Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

@article{Montgomery2007SevereDA,
  title={Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine},
  author={Stuart A. Montgomery and Siegfried Kasper},
  journal={International Clinical Psychopharmacology},
  year={2007},
  volume={22},
  pages={283-291}
}
  • S. Montgomery, S. Kasper
  • Published 1 September 2007
  • Medicine, Psychology
  • International Clinical Psychopharmacology
The efficacy of agomelatine in severe depression has been examined in three positive placebo-controlled studies and in a pooled analysis of the data from the three studies in patients treated with 25–50 mg agomelatine (n=357) and placebo (n=360). Agomelatine was significantly more effective than placebo in a subgroup of patients with severe depression with a severity of 25 or more on the Hamilton Depression Rating Scale 17-item scale in each individual study (P<0.05) and in the pooled analysis… Expand
Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist
Summary Agomelatine is a new antidepressant with an innovative pharmacological profile. It is a potent melatonergic agonist (MT 1 and MT 2 ) and also has 5-HT 2c antagonist properties. Agometatine'sExpand
The efficacy of agomelatine in previously-treated depressed patients
TLDR
Data from the subset of previously treated depressed patients indicate that agomelatine, due to its different mode of action, demonstrated antidepressant efficacy, and favorable side effect profile-with proven benefits in first-line treatment-is also an effective candidate for patients with major depressive disorder previously treated with other antidepressants. Expand
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
TLDR
There is evidence of the superiority of agomelatine over placebo and selected antidepressants, but it is questionable whether the magnitude of effect size is clinically significant and sample characteristics are relevant to the general patient population with major depressive disorder. Expand
Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
TLDR
The results showed significant antidepressant efficacy of agomelatine 50 mg/d, including a positive effect on sleep compared with placebo in outpatients with moderate to severe major depressive disorder. Expand
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
TLDR
Evidence suggesting that a clinically important difference between agomelatine and placebo in patients with unipolar major depression is unlikely is found and there was evidence of substantial publication bias. Expand
Sustained efficacy of agomelatine 10mg, 25mg, and 25–50mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months
TLDR
Long term agomelatine treatment improves both mood symptoms and social and occupational functioning of moderately to severely depressed patients and the one step titration 25-50 mg dose regimen was well tolerated and no unexpected adverse event was reported. Expand
The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-Analysis of Change on the Hamilton Rating Scales
TLDR
The available empirical evidence indicates that paroxetine provides only a modest advantage over placebo in treatment of anxiety and depression. Expand
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study
TLDR
In this study, agomelatine showed superior antidepressant efficacy over fluoxetine in treating patients with a severe episode of major depressive disorder after 8 weeks of treatment with a good tolerability profile. Expand
Agomelatine: The evidence for its place in the treatment of depression
TLDR
Agomelatine may represent a novel perspective in the treatment of acute depression and the improvement of sleep disturbances, the tolerability in terms of sexual side effects, and the lack of withdrawal symptoms after abrupt discontinuation of treatment may represent important clinical benefits compared to established antidepressants. Expand
Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.
TLDR
This meta-analysis assesses the overall antidepressant effect of Agomelatine by pooling all the published and unpublished studies available till date to find an effective antidepressant having similar efficacy with the currently used antidepressants. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
TLDR
The results support the prescription of agomelatine 25 mg as the usual therapeutic dose, and suggest that increasing the dose to 50 mg may be beneficial for some patients without reducing tolerability. Expand
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients
TLDR
The results on the primary efficacy scale were supported by significantly greater differences in favour of escitalopram on the Hamilton Anxiety, Hamilton Depression and Clinical Global Impression-Improvement and -Severity scales. Expand
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study
TLDR
It is demonstrated that agomelatine is efficient in the treatment of major depressive disorder and that 25 mg is the target dose. Expand
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder
TLDR
EscITALopram showed consistently superior efficacy compared to citalopram in the treatment of moderate to severe MDD on all efficacy parameters, and was similarly well tolerated. Expand
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
  • J. Olié, S. Kasper
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
  • 2007
TLDR
It is confirmed that agomelatine is effective in treating major depression, including the most severely depressed patients, with a good safety and tolerability profile, therefore providing physicians with an effective pharmacological approach to antidepressant therapy. Expand
The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis.
TLDR
It is indicated that the superiority of escitalopram over citaloprams is more apparent as the baseline severity of depression increases. Expand
An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.
TLDR
Sertraline was effective and well tolerated by older adults with major depression, although the drug-placebo difference was not large in this 8-week trial. Expand
Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study
  • L. Gram
  • Medicine
  • Psychopharmacology
  • 2004
TLDR
Citalopram was devoid of the typical autonomic side effects and orthostatic hypotension seen with clomipramine and seemed to be related in particular to the sleep items, but other items covering depression, retardation and anxiety/agitation also contributed to the difference in total score. Expand
Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia.
TLDR
Venlafaxine is an effective and well-tolerated antidepressant in hospitalized patients with major depression and melancholia and provides significantly greater improvement in the MADRS scores after 4 days and in the HAM-D scores after 1 week than did placebo. Expand
The optimal dosing regimen for citalopram‐a meta‐analysis of nine placebo‐controlled studies
TLDR
Analysis of patient subgroups revealed a tendency for those patients suffering from severe or recurrent depression to achieve better results with a higher dosage, while patients experiencing their first period of depression or with less severe depression responded well to the minimally effective dose of 20 mg. Expand
...
1
2
3
4
5
...